IL-6受体拮抗剂治疗危重型COVID-19肺炎:两项随机对照试验
CORIMUNO-19协作组开展两项嵌入队列的多中心开放标签贝叶斯随机对照试验,评估托珠单抗或沙利鲁单抗对危重型COVID-19肺炎的疗效。结果显示,第14天无需无创或有创通气且存活的患者比例在托珠单抗组与常规治疗组(47% vs 42%)、沙利鲁单抗组与常规治疗组(38% vs 33%)间均无显著差异,且两种药物均增加严重感染事件。
要点
- 托珠单抗或沙利鲁单抗未显著增加第14天无需通气且存活的患者数
- 两种IL-6受体拮抗剂均增加严重感染事件风险
- 至第90天死亡风险在托珠单抗组和沙利鲁单抗组与常规治疗组间无显著差异
核心结论
- 在危重型COVID-19患者中,抗IL-6受体药物未显著增加第14天无需无创或有创通气且存活的患者数。
- 托珠单抗和沙利鲁单抗均增加严重感染事件。
研究设计与样本
- 两项嵌入队列、研究者发起、多中心、开放标签、贝叶斯随机对照临床试验(TOCI-2和SARI-2)。
- TOCI-2试验纳入97例患者,随机接受常规治疗(n=46)或常规治疗+托珠单抗8 mg·kg-1(n=51)。
- SARI-2试验纳入91例患者,随机接受常规治疗(n=41)或常规治疗+沙利鲁单抗200 mg(n=50)。
- 两种药物均第1天静脉给药,若临床需要第3天重复。
主要发现
- 第14天无需无创或有创通气且存活比例:托珠单抗组47% vs 常规治疗组42%,中位后验风险比(HR)1.19(90%可信区间0.71-2.04),HR>1的后验概率71.4%。
- 第14天无需无创或有创通气且存活比例:沙利鲁单抗组38% vs 常规治疗组33%,中位后验HR 1.05(90%可信区间0.55-2.07),HR>1的后验概率54.9%。
- 至第90天死亡风险:托珠单抗组24% vs 常规治疗组30%(HR 0.67,95%CI 0.30-1.49)。
- 至第90天死亡风险:沙利鲁单抗组29% vs 常规治疗组39%(HR 0.74,95%CI 0.35-1.58)。
- 托珠单抗和沙利鲁单抗均增加严重感染事件。
临床怎么用
- 对于危重型COVID-19肺炎患者,不推荐常规使用托珠单抗或沙利鲁单抗以改善第14天无需通气的存活率。
- 使用IL-6受体拮抗剂时需警惕严重感染事件风险增加。
局限性
- 两项试验均为开放标签设计,可能引入偏倚。
- 样本量较小(TOCI-2 97例,SARI-2 91例),置信区间较宽。
- 研究时间为2020年3月至4月,结论外推至当前临床实践需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Our objective was to determine whether anti-interleukin (IL)-6 receptors improve outcomes of critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. We report on two cohort-embedded, investigator-initiated, multicentre, open-label, Bayesian randomised controlled clinical trials. METHODS: Patients were randomly assigned to receive either usual care (UC) or UC+tocilizumab (TCZ) 8 mg·kg-1 (TOCI-2 trial) or UC or UC+sarilumab (SARI) 200 mg (SARI-2 trial), both intravenously on day 1 and, if clinically indicated, on day 3. RESULTS: Between 31 March and 20 April 2020, 97 patients were randomised in the TOCI-2 trial, to receive UC (n=46) or UC+TCZ (n=51). At day 14, numbers of patients who did not need noninvasive ventilation (NIV) or mechanical ventilation (MV) and were alive with TCZ or UC were similar (47% versus 42%; median posterior hazard ratio (HR) 1.19, 90% credible interval (CrI) 0.71-2.04), with a posterior probability of HR >1 of 71.4%. Between 27 March and 4 April 2020, 91 patients were randomised in the SARI-2 trial, to receive UC (n=41) or UC+SARI (n=50). At day 14, numbers of patients who did not need NIV or MV and were alive with SARI or UC were similar (38% versus 33%; median posterior HR 1.05, 90% CrI 0.55-2.07), with a posterior probability of HR >1 of 54.9%. Overall, the risk of death up to day 90 was: UC+TCZ 24% versus UC 30% (HR 0.67, 95% CI 0.30-1.49) and UC+SARI 29% versus UC 39% (HR 0.74, 95% CI 0.35-1.58). Both TCZ and SARI increased serious infectious events. CONCLUSION: In critically ill patients with COVID-19, anti-IL-6 receptors did not significantly increase the number of patients alive without any NIV or MV by day 14.
引用
- Hermine O, Mariette X, Porcher R, et al. Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. Eur Respir J. 2022. PMID: 35115337. doi:10.1183/13993003.02523-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。